Envoy Medical, Inc Warrant financials
$0.0317+4.97%
Close Sep 24, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 |
|---|---|---|---|
| Revenue | $241.0K | $225.0K | $316.0K |
| Gross profit | -$633.0K | -$517.0K | -$473.0K |
| Gross margin | −262.7% | −229.8% | −149.7% |
| Operating income | -$22.3M | -$19.3M | -$18.4M |
| Net income | -$28.7M | -$28.0M | -$31.3M |
| Net margin | −11892.9% | −12432.4% | −9895.9% |
| Diluted EPS | $-1.23 | $-1.49 | $-2.54 |
| EBITDA | -$22.0M | -$19.1M | -$18.2M |
| Operating cash flow | -$18.2M | -$17.9M | -$17.1M |
| Free cash flow | -$18.4M | -$18.9M | -$17.2M |
| Diluted shares | 23.3M | 18.8M | 12.3M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|
| Cash & equivalents | $3.7M | $5.5M | $4.2M |
| Short-term investments | $0.00 | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 |
| Total assets | $8.6M | $11.5M | $8.3M |
| Total liabilities | $20.3M | $30.4M | $10.0M |
| Shareholders' equity | -$12.2M | -$18.8M | -$1.8M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology